Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URN010
MIFTS: 57

Urinary Tract Obstruction

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Urinary Tract Obstruction

About this section

MalaCards integrated aliases for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction 12 15 17 71
Obstructive Uropathy 12 54 15
Urinary Obstruction 12
Urologic Diseases 71

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:5200
ICD9CM 34 599.6 599.60
NCIt 49 C3675 C79805
SNOMED-CT 67 7163005
ICD10 32 N13.9
UMLS 71 C0042075 C0178879
Sources

Summaries for Urinary Tract Obstruction

About this section
MalaCards based summary : Urinary Tract Obstruction, also known as obstructive uropathy, is related to obstructive nephropathy and ureteral obstruction, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary Tract Obstruction is BNC2 (Basonuclin 2), and among its related pathways/superpathways are HIV Life Cycle and Developmental Biology. The drugs Alfuzosin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and testes, and related phenotypes are growth/size/body region and behavior/neurological

Sources

Related Diseases for Urinary Tract Obstruction

About this section

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 468)
# Related Disease Score Top Affiliating Genes
1 obstructive nephropathy 32.6 TGFB1 SMAD3 SMAD2 REN MIR299 EGF
2 ureteral obstruction 31.5 TGFB1 PTGS2 AQP2
3 chronic pyelonephritis 31.2 UMOD REN B2M ALB
4 interstitial cystitis 31.2 UMOD HBEGF EGF
5 hydronephrosis 31.1 TGFB1 REN NAGLU MIR299 EGF CCL2
6 acute cystitis 31.1 UMOD REN KLK3 CCL2 ALB
7 schistosomiasis 31.0 TGFB1 GGT1 CCL2 ALB
8 renal hypertension 31.0 REN FN1 ALB
9 hyperuricemia 30.9 UMOD REN GGT1 ALB
10 end stage renal failure 30.9 UMOD TGFB1 REN PTGS2 FN1 ALB
11 acute kidney failure 30.8 UMOD REN EGF B2M ALB
12 adenocarcinoma 30.8 TGFB1 SMAD3 PTGS2 PIK3CA EGF
13 pyelitis 30.8 UMOD REN B2M ALB
14 cystitis 30.8 UMOD PTGS2 HBEGF GDNF EGF CCL2
15 adenoma 30.7 SMAD3 REN PTGS2 PIK3CA
16 kidney disease 30.7 UMOD TGFB1 REN NAGLU CCL2 B2M
17 polycystic kidney disease 30.7 REN EGF AQP2 ALB
18 chronic kidney disease 30.7 UMOD TGFB1 REN CCL2 B2M AQP2
19 cakut 30.7 UMOD REN GDNF
20 pyelonephritis 30.6 UMOD NAGLU CCL2 AQP2 ALB
21 vesicoureteral reflux 1 30.6 UMOD TGFB1 REN NAGLU GDNF B2M
22 gastroesophageal reflux 30.6 TGFB1 PTGS2 EGF CCL2
23 interstitial nephritis 30.6 UMOD REN B2M ALB
24 acute kidney tubular necrosis 30.5 UMOD REN NAGLU GGT1 ALB
25 nephrogenic systemic fibrosis 30.5 TGFB1 SMAD3 SMAD2 PIK3CA
26 lymphocele 30.5 KLK3 ALB
27 glomerulonephritis 30.5 TGFB1 SMAD2 FN1 CCL2 B2M ALB
28 nephrolithiasis, calcium oxalate 30.5 UMOD REN NAGLU CCL2 AQP2 ALB
29 clear cell adenocarcinoma 30.4 SMAD3 SMAD2 PIK3CA KLK3
30 cystic kidney disease 30.4 UMOD REN EGF B2M AQP2 ALB
31 uremia 30.3 REN B2M ALB
32 pyuria 30.3 KLK3 B2M ALB
33 urinary system disease 30.3 UMOD REN NAGLU KLK3 B2M ALB
34 vascular disease 30.3 TGFB1 REN PTGS2 FN1 CCL2 ALB
35 inflammatory bowel disease 30.3 TGFB1 SMAD3 SMAD2 PTGS2 EGF CCL2
36 ovarian disease 30.3 REN PIK3CA EGF ALB
37 myeloma, multiple 30.2 FN1 EGF CCL2 B2M ALB
38 autosomal dominant polycystic kidney disease 30.2 TGFB1 REN EGF CCL2 AQP2 ALB
39 renal fibrosis 30.2 TGFB1 SMAD3 SMAD2 REN FN1 CCL2
40 polycystic kidney disease 4 with or without polycystic liver disease 30.1 UMOD EGF AQP2
41 diabetes mellitus 30.0 UMOD TGFB1 REN PTGS2 PIK3CA NAGLU
42 pulmonary hypertension 30.0 SMAD3 SMAD2 REN PTGS2 FN1 CCL2
43 prostate cancer 30.0 TGFB1 SMAD3 SMAD2 PTGS2 PIK3CA KLK3
44 neuroblastoma 29.5 PTGS2 PIK3CA GDNF FN1 EGF ALB
45 ovarian cancer 29.4 TGFB1 SMAD3 SMAD2 PTGS2 PIK3CA KLK3
46 lower urinary tract obstruction, congenital 12.9
47 fetal lower urinary tract obstruction 12.7
48 obsolete: pulmonary aortic stenosis obstructive uropathy 12.4
49 kashani strom utley syndrome 11.9
50 renal hypodysplasia/aplasia 1 11.8

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 19)


Acute Cystitis Acute Kidney Failure
Bladder Cancer Bladder Neck Obstruction
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Paralytic Ileus
Prostate Calculus Prostate Cancer
Prostatic Hypertrophy Prostatitis
Protein-Energy Malnutrition Ureterolithiasis
Urethral Stricture

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:



Diseases related to Urinary Tract Obstruction
Sources

Symptoms & Phenotypes for Urinary Tract Obstruction

About this section

UMLS symptoms related to Urinary Tract Obstruction:


dysuria, polyuria, urgency of micturition, other and unspecified genitourinary symptoms, renal colic, pain in urethra, uti symptoms, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, bladder discomfort, renal pain, urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 AQP2 B2M BNC2 EGF FN1 GDNF
2 behavior/neurological MP:0005386 10.39 AQP2 BNC2 GDNF GGT1 HBEGF NAGLU
3 cardiovascular system MP:0005385 10.38 ALB B2M FN1 GDNF HBEGF NAGLU
4 immune system MP:0005387 10.35 ALB B2M CCL2 EGF FN1 GDNF
5 cellular MP:0005384 10.34 ALB B2M FN1 GDNF GGT1 NAGLU
6 homeostasis/metabolism MP:0005376 10.31 ALB AQP2 B2M FN1 GGT1 HBEGF
7 mortality/aging MP:0010768 10.28 ALB AQP2 B2M BNC2 FN1 GDNF
8 hematopoietic system MP:0005397 10.25 AQP2 B2M FN1 GDNF GGT1 NAGLU
9 endocrine/exocrine gland MP:0005379 10.24 ALB B2M EGF GDNF GGT1 PIK3CA
10 integument MP:0010771 10.23 AQP2 B2M EGF FN1 GGT1 HBEGF
11 digestive/alimentary MP:0005381 10.2 ALB B2M BNC2 EGF GDNF PTGS2
12 liver/biliary system MP:0005370 10.03 ALB B2M FN1 NAGLU PTGS2 SMAD2
13 nervous system MP:0003631 10 B2M FN1 GDNF HBEGF NAGLU PIK3CA
14 muscle MP:0005369 9.97 ALB FN1 GDNF HBEGF PIK3CA PTGS2
15 neoplasm MP:0002006 9.92 ALB B2M FN1 PIK3CA PTGS2 SMAD2
16 renal/urinary system MP:0005367 9.85 ALB AQP2 GDNF GGT1 NAGLU PTGS2
17 reproductive system MP:0005389 9.73 AQP2 B2M EGF FN1 GDNF GGT1
18 skeleton MP:0005390 9.36 BNC2 FN1 GGT1 HBEGF NAGLU PIK3CA
Sources

Drugs & Therapeutics for Urinary Tract Obstruction

About this section

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 220)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
2
leucovorin Approved Phase 4 58-05-9 6006 143
3
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
4
Hydroxychloroquine Approved Phase 4 118-42-3 3652
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
7
Mirabegron Approved Phase 4 223673-61-8 9865528
8
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
9
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
10
Iodine Approved, Investigational Phase 4 7553-56-2 807
11
Povidone Approved Phase 4 9003-39-8
12
Povidone-iodine Approved Phase 4 25655-41-8
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14
Cimetropium Experimental, Investigational Phase 4 150521-16-7
15
Uric acid Investigational Phase 4 69-93-2 1175
16 Autonomic Agents Phase 4
17 Parasympatholytics Phase 4
18 Antitubercular Agents Phase 4
19 Antirheumatic Agents Phase 4
20 Vitamins Phase 4
21 Vitamin B Complex Phase 4
22 Vitamin B9 Phase 4
23 Folate Phase 4
24 Mydriatics Phase 4
25 Antiemetics Phase 4
26 Gastrointestinal Agents Phase 4
27 Adjuvants, Anesthesia Phase 4
28 Butylscopolammonium Bromide Phase 4
29 Antihypertensive Agents Phase 4
30 interferons Phase 4
31 Antiparasitic Agents Phase 4
32 Antiprotozoal Agents Phase 4
33 Angiotensin II Type 1 Receptor Blockers Phase 4
34 Giapreza Phase 4
35 Angiotensin Receptor Antagonists Phase 4
36 Immunoglobulin A Phase 4
37 Antimalarials Phase 4
38 Angiotensinogen Phase 4
39 Interferon-alpha Phase 4
40 Neurotransmitter Agents Phase 4
41 Adrenergic Agents Phase 4
42 Cholinergic Agents Phase 4
43 Cholinergic Antagonists Phase 4
44 Adrenergic Agonists Phase 4
45 Adrenergic beta-Agonists Phase 4
46 Muscarinic Antagonists Phase 4
47 Adrenergic beta-3 Receptor Agonists Phase 4
48 Solifenacin succinate Phase 4 242478-38-2
49 Anesthetics Phase 4
50 Anticonvulsants Phase 4

Interventional clinical trials:

(show top 50) (show all 160)
# Name Status NCT ID Phase Drugs
1 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
2 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a History of Upper Urinary Tract Infections:a Multicentre Randomised Study Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
3 The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones Unknown status NCT00451061 Phase 4 Alfuzosin;Tamsulosin
4 Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty Unknown status NCT02444013 Phase 4 Folic acid;Placebo
5 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
6 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
7 A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Completed NCT03256838 Phase 4 Ferric Citrate
8 Interest of MR Urography in the Evaluation of Functional Consequences of Urinary Tract in Children and Adults Completed NCT00301470 Phase 4
9 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
10 Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures Recruiting NCT02805504 Phase 4 Exparel;Marcaine
11 Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery Recruiting NCT03591289 Phase 4 NMB with rocuronium bromide
12 A Randomized Trial of Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal to Reduce Bacteriuria and Catheter-Associated Urinary Tract Infections Terminated NCT03447639 Phase 4 Povidone-iodine irrigation
13 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
14 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
15 Assessment of Analgesic Efficacy of Intranasal Desmopressin in the Treatment of Acute Pain in Patients With Renal Colic Unknown status NCT01742689 Phase 3 Desmopressin intranasal spray;Placebo intranasal spray;Indomethacin suppository
16 Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Completed NCT01061073 Phase 3 Omexel;spasfon
17 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome Completed NCT00239317 Phase 3 Tamusulosin
18 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome Completed NCT00239265 Phase 3 Tamuslosin
19 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
20 An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Completed NCT03492281 Phase 3 vibegron;Placebos;Tolterodine Tartrate ER
21 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
22 An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Completed NCT03583372 Phase 3 Vibegron;placebos;Tolterodine Tartrate ER
23 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
24 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
25 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
26 A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258102 Phase 3 Levofloxacin
27 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
28 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
29 Saw Palmetto Extract In Benign Prostatic Hyperplasia Completed NCT00037154 Phase 3 Saw Palmetto
30 Self-management for Men With Uncomplicated Lower Urinary Tract Symptoms. A Randomised Controlled Trial Against Standard Therapy Completed NCT00270309 Phase 3
31 A Multicenter, Randomized, Open‐Label, Active‐Controlled, Parallel Study to Assess the Efficacy and Safety of Ferric Citrate Capsules for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Recruiting NCT03984760 Phase 3 Ferric Citrate;Sevelamer Carbonate
32 Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot Active, not recruiting NCT03927781 Phase 3 Pregabalin 300mg
33 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
34 A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER Terminated NCT01310803 Phase 3 VALSTAR - Maintenance Therapy
35 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
36 A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer Terminated NCT01200992 Phase 3
37 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
38 Randomized Controlled Trial of Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Unknown status NCT01552824 Phase 2
39 A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
40 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
41 A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function Completed NCT02118714 Phase 2 Atrasentan
42 RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes) Completed NCT02316821 Phase 2 RTA 402;Placebo
43 Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells Completed NCT02291432 Phase 1, Phase 2
44 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
45 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
46 A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI) Completed NCT01505634 Phase 2 Relebactam 250 mg;Relebactam 125 mg;imipenem/cilastatin 500 mg;Placebo to relebactam;Ciprofloxacin
47 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Recruiting NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
48 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
49 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
50 Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2

Search NIH Clinical Center for Urinary Tract Obstruction

Sources

Genetic Tests for Urinary Tract Obstruction

About this section
Sources

Anatomical Context for Urinary Tract Obstruction

About this section

MalaCards organs/tissues related to Urinary Tract Obstruction:

40
Kidney, Prostate, Testes, Heart, Bone, Liver, Cervix
Sources

Publications for Urinary Tract Obstruction

About this section

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 3804)
# Title Authors PMID Year
1
New paradigms for advanced prostate cancer. 54 61
17554403 2007
2
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. 54 61
15017212 2004
3
Glial cell line derived neurotrophic factor is expressed by epithelia of human renal dysplasia. 54 61
12441997 2002
4
[Urinary enzyme excretion in childhood uropathy]. 54 61
12434629 2002
5
[Screening for early detection of prostate cancer (first experience in Israel)]. 54 61
11242898 2001
6
Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction. 54 61
10576204 1999
7
Clinical pharmacokinetics and pharmacodynamics of finasteride. 54 61
8846625 1996
8
Tamm-Horsfall protein: are serum levels a marker for urinary tract obstruction? 54 61
7696106 1994
9
[Evaluation of renal function and prediction of renal functional recovery in children with unilateral hydronephrosis using renal pelvic urine]. 54 61
1282579 1992
10
Prenatal Diagnosis of Megacystitis and Hydronephrosis in an Equine Fetus: How Transabdominal Ultrasonography Can Help to Diagnose Fetal Abnormalities. 61
31952643 2020
11
Two-step treatment model for the adult patients with an obstructed kidney functioning below 10% of its capacity: a pilot study. 61
31655937 2020
12
Re: Common Clinical Markers Predict End-Stage Renal Disease in Children with Obstructive Uropathy. 61
31710546 2020
13
Diabetic ketoacidosis complicated by emphysematous pyelonephritis: a case report and literature review. 61
31996190 2020
14
Fetal Cystoscopy and Vesicoamniotic Shunting in Lower Urinary Tract Obstruction: Long-Term Outcome and Current Technical Limitations. 61
31401627 2020
15
Not just a simple inguinal hernia. A rare case of an inguino-scrotal ureter! 61
31641615 2020
16
Myositis Induced by Isotretinoin: A Case Report and Literature Review. 61
31958335 2020
17
Etiology and management of Early pregnancy Renal Anhydramnios (EPRA): Is there a place for serial amnioinfusions? 61
32003482 2020
18
Antenatal hydronephrosis and fetal urine sampling. 61
30629771 2020
19
Prenatal diagnosis and postnatal outcome of anterior urethral anomalies. 61
31654578 2020
20
Clinical, morphologic and histological features of chronic pyelonephritis: An 8-year review. 61
32003360 2020
21
Gross Hematuria as a Presenting Feature of Posterior Urethral Valves in a Neonate with Normal Antenatal Sonograms. 61
31936198 2020
22
Ureteroneocystostomy herniation leading to obstructive uropathy 10 years postrenal transplant: A rare case report. 61
32015627 2020
23
Giant hydronephrotic kidney in adolescence- A rare case report and a review of the literature. 61
31641609 2020
24
A case of solitary rectal diverticulum presenting with a large retrorectal abscess. 61
31890199 2020
25
Prospective audit of complications after ultrasonography-guided percutaneous nephrostomy for upper urinary tract obstruction using modified Clavien classification system. 61
32015614 2020
26
[Focused Abdominal Ultrasound in Emergency, Perioperative and Intensive Care Medicine]. 61
31958858 2020
27
Single-Use Versus Reusable Digital Flexible Ureteroscopes for the Treatment of Renal Calculi: A Prospective Multicenter Randomized Controlled Trial. 61
31432716 2020
28
Obstructive uropathy secondary to ureteral inguinoscrotal hernia. 61
31851475 2020
29
Evaluation of dynamic thiol-disulphide homeostasis in obstructive uropathy. 61
31955364 2020
30
[Nephroprotective effect of calcium channel blocker lercanidipine in treatment of patients with urolithiasis and urinary tract obstruction and monitoring of the serum cytokine profile]. 61
31808632 2019
31
CAKUT and Autonomic Dysfunction Caused by Acetylcholine Receptor Mutations. 61
31708116 2019
32
Obstructive uropathy associated with rheumatoid arthritis successfully treated with steroids and immunosuppressive therapy: A case report. 61
31852165 2019
33
Post-obstructive Diuresis: A Cautionary Tale. 61
31938619 2019
34
Renal elasticity and perfusion changes associated with fibrosis on ultrasonography in a rabbit model of obstructive uropathy. 61
31858205 2019
35
Neonatal obstructive nephropathy induces necroptosis and necroinflammation. 61
31819111 2019
36
Poor access to kidney disease management services in susceptible patient populations in rural Australia is associated with increased aeromedical retrievals for acute renal care. 61
31821680 2019
37
Prediction model of postnatal renal function in fetuses with lower urinary tract obstruction (LUTO)-Development and internal validation. 61
31659787 2019
38
Fetal cardiac findings and hemodynamic changes associated with severe lower urinary tract obstruction in utero. 61
30908816 2019
39
Retrospective Analysis of the Role of Antibiotic Prophylaxis in the Placement and Replacement of Percutaneous Nephrostomy Catheters in Patients with Malignant Ureteral Obstruction. 61
31800348 2019
40
Easy Method for Percutaneous Nephrostomy Placement with Transrectal Ultrasonography Probe. 61
31660792 2019
41
[Bilateral acute purulent destructive pyelonephritis after retrograde ureteroscopy and lithotripsy]. 61
31808644 2019
42
[Specific features of the immune status and blebbing of the plasmatic membrane of lymphocytes patients with urolithiasis complicated by the pyelonephritis]. 61
31808634 2019
43
[Predictors of perioperative complications in children with obstructive uropathy]. 61
31808640 2019
44
Unusual presentation and urinary tract obstruction due to disseminated intra-abdominal eumycetomas caused by Curvularia species in a dog. 61
31667057 2019
45
Prenatal diagnosis of congenital megalourethra in the second trimester of pregnancy. 61
32021712 2019
46
Noncirrhotic hyperammonemia after deceased donor kidney transplantation: A case report. 61
31347272 2019
47
Eighteen-Year Review of Resident Performance on the American Urological Association In-Service Examination. 61
31785278 2019
48
Balloon catheterization in fetal lower urinary tract obstruction: an observational study of 10 fetuses. 61
31763721 2019
49
Effects on renal outcome of concomitant acute pyelonephritis, acute kidney injury and obstruction duration in obstructive uropathy by urolithiasis: a retrospective cohort study. 61
31685503 2019
50
Minimally invasive management of acute ureteral obstruction and severe infection caused by upper urinary tract calculi. 61
31796723 2019
Sources

Variations for Urinary Tract Obstruction

About this section
Sources

Expression for Urinary Tract Obstruction

About this section
Search GEO for disease gene expression data for Urinary Tract Obstruction.
Sources

Pathways for Urinary Tract Obstruction

About this section

Pathways related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
HIV Life Cycle 65
Show member pathways
 13.68 TGFB1 SMAD3 SMAD2 PIK3CA HBEGF FN1
2
Developmental Biology 65
Show member pathways
 13.44 TGFB1 SMAD3 SMAD2 PIK3CA HBEGF GDNF
3
Cytokine Signaling in Immune system 65
Show member pathways
 13.2 TGFB1 PTGS2 PIK3CA HBEGF GDNF FN1
4
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.08 TGFB1 SMAD3 SMAD2 PIK3CA EGF CCL2
5
p70S6K Signaling 63
Show member pathways
 12.99 TGFB1 REN PTGS2 HBEGF EGF CCL2
6
Endometrial cancer 36
Show member pathways
 12.78 TGFB1 SMAD3 SMAD2 PIK3CA KLK3 EGF
7
Gastric cancer 36
Show member pathways
 12.72 TGFB1 SMAD3 SMAD2 PIK3CA EGF
8
Pathways in cancer 36
12.65 TGFB1 SMAD3 SMAD2 PTGS2 PIK3CA KLK3
9
Folate Metabolism 1
Show member pathways
 12.27 PTGS2 GGT1 CCL2 ALB
10
Human T-cell leukemia virus 1 infection 36
12.22 TGFB1 SMAD3 SMAD2 PIK3CA B2M
11
Proteoglycans in cancer 36
12.16 TGFB1 SMAD2 PIK3CA HBEGF FN1
12
Cellular senescence (KEGG) 36
12.09 TGFB1 SMAD3 SMAD2 PIK3CA
13
Colorectal Cancer Metastasis 63
12.02 TGFB1 SMAD3 SMAD2 PTGS2 EGF
14
FoxO signaling pathway 36
Show member pathways
 12.01 TGFB1 SMAD3 PIK3CA EGF
15
TGF-beta Signaling Pathway (WikiPathways) 1
11.99 TGFB1 SMAD3 SMAD2 FN1
16
Spinal Cord Injury 1
11.93 TGFB1 PTGS2 GDNF CCL2
17
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.9 TGFB1 SMAD3 PIK3CA KLK3 HBEGF EGF
18
Interleukin-4 and 13 signaling 65
11.88 TGFB1 PTGS2 FN1 CCL2
19
TGF-beta signaling pathway (KEGG) 36
11.82 TGFB1 SMAD3 SMAD2
20
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.82 TGFB1 SMAD3 SMAD2
21
Small cell lung cancer 36
11.81 PTGS2 PIK3CA FN1
22
Angiogenesis (CST) 4
11.75 TGFB1 REN PTGS2 CCL2
23
SMAD2/3 MH2 Domain Mutants in Cancer 65
Show member pathways
 11.72 TGFB1 SMAD3 SMAD2
24
Development_TGF-beta receptor signaling 22
11.69 TGFB1 SMAD3 SMAD2
25
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.67 TGFB1 PTGS2 CCL2
26
TGF-beta receptor signaling activates SMADs 65
Show member pathways
 11.66 TGFB1 SMAD3 SMAD2
27
Regulation of Telomerase 1
11.63 TGFB1 SMAD3 EGF
28
Lung fibrosis 1
11.59 TGFB1 EGF CCL2
29
Cell adhesion_ECM remodeling 22
11.57 KLK3 HBEGF FN1
30
TGF-beta receptor signaling (Pathway Interaction Database) 1
11.49 TGFB1 SMAD3 SMAD2
31
Hepatitis C and Hepatocellular Carcinoma 1
11.48 TGFB1 SMAD3 PTGS2
32
Cell adhesion_Plasmin signaling 22
11.46 TGFB1 PIK3CA FN1
33
TGF-beta Receptor Signaling (WikiPathways) 1
11.43 TGFB1 SMAD3 SMAD2 EGF
34
Extracellular vesicle-mediated signaling in recipient cells 1
11.19 TGFB1 SMAD3 SMAD2
35
IL-2 Gene Expression in Activated and Quiescent T-Cells 63
Show member pathways
 11.12 TGFB1 SMAD3 SMAD2 PIK3CA HBEGF EGF
36
AGE-RAGE signaling pathway in diabetic complications 36
11.1 TGFB1 SMAD3 SMAD2 PIK3CA FN1 CCL2
37
IL1 and megakaryocytes in obesity 1
11.08 PIK3CA HBEGF CCL2
38
TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition 1
10.71 TGFB1 SMAD3 SMAD2 FN1
Sources

GO Terms for Urinary Tract Obstruction

About this section

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 UMOD NAGLU KLK3 GGT1 FN1 EGF
2 extracellular region GO:0005576 9.9 UMOD TGFB1 REN KLK3 HBEGF GDNF
3 SMAD protein complex GO:0071141 9.37 SMAD3 SMAD2
4 extracellular space GO:0005615 9.36 TGFB1 REN KLK3 HBEGF GGT1 GDNF
5 heteromeric SMAD protein complex GO:0071144 9.26 SMAD3 SMAD2
6 platelet alpha granule lumen GO:0031093 9.26 TGFB1 FN1 EGF ALB

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 TGFB1 SMAD3 SMAD2 FN1 EGF
2 negative regulation of cell proliferation GO:0008285 10.02 UMOD TGFB1 SMAD3 SMAD2 PTGS2
3 positive regulation of cell proliferation GO:0008284 10.02 TGFB1 PTGS2 HBEGF GDNF FN1 EGF
4 positive regulation of cell migration GO:0030335 9.96 TGFB1 SMAD3 HBEGF EGF
5 cellular protein metabolic process GO:0044267 9.94 KLK3 FN1 B2M ALB
6 cytokine-mediated signaling pathway GO:0019221 9.93 TGFB1 PTGS2 PIK3CA FN1 CCL2
7 positive regulation of protein kinase B signaling GO:0051897 9.9 TGFB1 PIK3CA HBEGF EGF
8 MAPK cascade GO:0000165 9.88 TGFB1 HBEGF GDNF EGF CCL2
9 response to organic substance GO:0010033 9.85 TGFB1 REN PTGS2
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 TGFB1 PTGS2 PIK3CA
11 platelet degranulation GO:0002576 9.83 TGFB1 FN1 EGF ALB
12 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.82 TGFB1 SMAD3 SMAD2
13 angiogenesis GO:0001525 9.8 PTGS2 PIK3CA FN1 EGF CCL2
14 SMAD protein signal transduction GO:0060395 9.79 TGFB1 SMAD3 SMAD2
15 positive regulation of epithelial to mesenchymal transition GO:0010718 9.75 TGFB1 SMAD3 SMAD2
16 protein kinase B signaling GO:0043491 9.74 TGFB1 PIK3CA CCL2
17 positive regulation of protein import into nucleus GO:0042307 9.73 TGFB1 SMAD3 PTGS2
18 endoderm development GO:0007492 9.69 TGFB1 SMAD3 SMAD2
19 ERBB2 signaling pathway GO:0038128 9.67 PIK3CA HBEGF EGF
20 wound healing GO:0042060 9.67 TGFB1 SMAD3 SMAD2 FN1
21 lens fiber cell differentiation GO:0070306 9.66 TGFB1 SMAD3
22 response to cholesterol GO:0070723 9.65 TGFB1 SMAD2
23 nodal signaling pathway GO:0038092 9.65 SMAD3 SMAD2
24 pericardium development GO:0060039 9.64 SMAD3 SMAD2
25 embryonic foregut morphogenesis GO:0048617 9.63 SMAD3 SMAD2
26 primary miRNA processing GO:0031053 9.63 SMAD3 SMAD2
27 common-partner SMAD protein phosphorylation GO:0007182 9.61 TGFB1 SMAD2
28 positive regulation of extracellular matrix assembly GO:1901203 9.59 TGFB1 SMAD3
29 regulation of striated muscle tissue development GO:0016202 9.58 TGFB1 SMAD3
30 epidermal growth factor receptor signaling pathway GO:0007173 9.56 TGFB1 PIK3CA HBEGF EGF
31 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.5 TGFB1 SMAD3 SMAD2
32 paraxial mesoderm morphogenesis GO:0048340 9.46 SMAD3 SMAD2
33 ureteric bud development GO:0001657 9.46 TGFB1 SMAD3 SMAD2 GDNF
34 evasion or tolerance of host defenses by virus GO:0019049 9.43 TGFB1 SMAD3
35 SMAD protein complex assembly GO:0007183 9.13 TGFB1 SMAD3 SMAD2
36 regulation of binding GO:0051098 8.8 TGFB1 SMAD3 SMAD2

Molecular functions related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.85 TGFB1 SMAD3 SMAD2 PTGS2 GDNF B2M
2 growth factor activity GO:0008083 9.46 TGFB1 HBEGF GDNF EGF
3 co-SMAD binding GO:0070410 9.4 SMAD3 SMAD2
4 type I transforming growth factor beta receptor binding GO:0034713 9.32 TGFB1 SMAD2
5 primary miRNA binding GO:0070878 9.26 SMAD3 SMAD2
6 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 8.96 SMAD3 SMAD2
7 transforming growth factor beta receptor binding GO:0005160 8.8 TGFB1 SMAD3 SMAD2
Sources

Sources for Urinary Tract Obstruction

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....